| Home | E-Submission | Sitemap | Editorial Office |  
Korean J Urol Oncol > Volume 2(2); 2004 > Article
The Korean Journal of Urological Oncology 2004;2(2): 60-65.
진행성 요로상피암에서 Gemcitabine과 Cisplatin 병합 화학요법의 효용성
김상훈, 이승주, 이지열, 조수연, 김세웅, 이충범, 조대행, 강성학, 황태곤, 조용현
가톨릭대학교 의과대학 비뇨기과학교실
Efficacy and Toxicity of Gemcitabine plus Cisplatine Chemotherapy in Advanced Urothelial Cancer
Sang Hoon Kim , Seung-Ju Lee , Ji Youl Lee , Su Yeon Cho , Sae Woong Kim , Choong Bum Lee , Dae Haeng Cho , Sung Hak Kang , Tae Kon Hwang , Yong-Hyun Cho
Department of Urology, The Catholic University of Korea Medical College, Seoul, Korea
Published online: June 30, 2004.
Efficacy and toxicity of gemicitabine plus cisplatin(GC) and those of other chemotherapy(MVAC or MVEC) were compared in patients with locally advanced or metastatic urothelial cancer.
Materials and Methods:
Seventy-five patients with advanced urothelial cancer were treated wth gemcitabine 1,000mg/m2 intravenously for 30 minutes on days 1, 8 and 15 and cisplatinr 70mg/m2 for 1 hour on day 2 of each 28-day cycle. 52 of them who completed more than 3 cycles were evaluated on the response and toxicity. The full dose of the drugs was administered in all patients.
Sixteen of the 52 patients achieved a complete respone(31%) and 3 achieved a partial response(6%) showing an overal response rate 37%. There were 2 complete response and 2 partial response, for an overall response rate of 4 of 10 patients who had received prior MVAC(methotrexate, vinblastine, doxorubicin, cyclophosphamide) or MVEC(methotrexate, vinblastin, epirubicin, cisplatin) chemotherapy. The main toxicity was myelosupression, with an incidence of 30% thrombocytopenia, 45% leukopenia, and 22% anemia, but only 4% of grade 3 to 4. Other toxicity was mild, with a low incidence of 45% nausea and vomiting. and only 8% of grade 3 to 4.
Gemcitabine plus cisplatin combination chemotherapy provides a similar survival advantage to MVAC or MVEC with a better safety profile and tolerability in advanced urothelial cancer. The long-term follow-up and further studies is warranted. (Korean J Uro-Oncol 2004;2:60-65)
No abstract available
Key Words: Gemcitabine; Advanced urothelial cancer; Efficacy; Toxicity
Editorial Office
Department of Urology, Chung-Ang University Hospital
102 Heukseok-ro, Dongjak-gu, Seoul 06973, Korea
Tel: +82-2-6299-1819   Fax: +82-2-6294-1406   E-mail: journal@kjuo.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © The Korean Urological Oncology Society and The Korean Prostate Society. All rights reserved.                 developed in m2community
Close layer
prev next